Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bahcall

Showing results (111-120 of 131) with videos related to

Pageof 14
Sort By:
Journal of Medicinal Chemistry|April 18, 2018
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)Chelsea E Powell, Yang Gao, Li Tan, et al.
The Astrophysical Journal|November 7, 1999
The Discovery of a High-Redshift Quasar without Emission Lines from Sloan Digital Sky Survey Commissioning DataFan, Strauss, Gunn, et al.
Nature|March 3, 2022
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancersYoshihisa Kobayashi, Chhayheng Chhoeu, Jiaqi Li, et al.
Cancer Research|June 7, 2015
Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2Junko Tanizaki, Dalia Ercan, Marzia Capelletti, et al.
The Astrophysical Journal|June 13, 2000
The Missing Link: Early Methane ("T") Dwarfs in the Sloan Digital Sky SurveyLeggett, Geballe, Fan, et al.
Cancer Research|April 2, 2017
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 InhibitorsTakayuki Kosaka, Junko Tanizaki, Raymond M Paranal, et al.
Cancer Discovery|October 4, 2016
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung CancerMagda Bahcall, Taebo Sim, Cloud P Paweletz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanomaSteven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.
Molecular Cancer Therapeutics|November 18, 2021
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent ResistanceMagda Bahcall, Cloud P Paweletz, Yanan Kuang, et al.
Cell Genomics|September 9, 2022
Workshop proceedings: GWAS summary statistics standards and sharingJacqueline A L MacArthur, Annalisa Buniello, Laura W Harris, et al.
Pageof 14

Showing results (111-120 of 131) with videos related to

Sort By:
Pageof 14
Journal of Medicinal Chemistry|April 18, 2018
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)Chelsea E Powell, Yang Gao, Li Tan, et al.
The Astrophysical Journal|November 7, 1999
The Discovery of a High-Redshift Quasar without Emission Lines from Sloan Digital Sky Survey Commissioning DataFan, Strauss, Gunn, et al.
Nature|March 3, 2022
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancersYoshihisa Kobayashi, Chhayheng Chhoeu, Jiaqi Li, et al.
Cancer Research|June 7, 2015
Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2Junko Tanizaki, Dalia Ercan, Marzia Capelletti, et al.
The Astrophysical Journal|June 13, 2000
The Missing Link: Early Methane ("T") Dwarfs in the Sloan Digital Sky SurveyLeggett, Geballe, Fan, et al.
Cancer Research|April 2, 2017
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 InhibitorsTakayuki Kosaka, Junko Tanizaki, Raymond M Paranal, et al.
Cancer Discovery|October 4, 2016
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung CancerMagda Bahcall, Taebo Sim, Cloud P Paweletz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanomaSteven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.
Molecular Cancer Therapeutics|November 18, 2021
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent ResistanceMagda Bahcall, Cloud P Paweletz, Yanan Kuang, et al.
Cell Genomics|September 9, 2022
Workshop proceedings: GWAS summary statistics standards and sharingJacqueline A L MacArthur, Annalisa Buniello, Laura W Harris, et al.
Pageof 14